SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Swain MG. Fatigue in chronic disease. Clin Sci (Lond) 2000; 99: 18.
  • 2
    Flowers N, Wolfe F. What do rheumatologists do in their practices? [abstract]. Arthritis Rheum 1998; 41: 337.
  • 3
    Cella D, Davis K, Breitbart W, Curt G, and the Fatigue Coalition. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001; 19: 338591.
  • 4
    Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 224655.
  • 5
    Haythornthwaite JA, Heinberg LJ, McGuire L. Psychologic factors in scleroderma. Rheum Dis Clin North Am 2003; 29: 42739.
  • 6
    Thombs BD, Taillefer SS, Hudson M, Baron M. Depression in patients with systemic sclerosis: a systematic review of the evidence. Arthritis Rheum 2007; 57: 108997.
  • 7
    Richards HL, Herrick AL, Griffin K, Gwilliam PD, Loukes J, Fortune DG. Systemic sclerosis: patients' perceptions of their condition. Arthritis Rheum 2003; 49: 68996.
  • 8
    Suarez-Almazor ME, Kallen MA, Roundtree AK, Mayes M. Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol 2007; 34: 171826.
  • 9
    Van Lankveld WG, Vonk MC, Teunissen H, van den Hoogen FH. Appearance self-esteem in systemic sclerosis: subjective experience of skin deformity and its relationship with physician-assessed skin involvement, disease status and psychological variables. Rheumatology (Oxford) 2007; 46: 8726.
  • 10
    Thombs BD, Bassel M, McGuire L, Smith MT, Hudson M, Haythornthwaite JA. A systematic comparison of fatigue levels in systemic sclerosis with general population, cancer and rheumatic disease samples. Rheumatology (Oxford) 2008; 47: 155963.
  • 11
    Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 2004; 91: 8228.
  • 12
    Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 13
    Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum 2007; 57: 42939.
  • 14
    Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum 2004; 33: 24963.
  • 15
    Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 12815.
  • 16
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 17
    Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 198491.
  • 18
    Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? Med Care 1996; 34: 7384.
  • 19
    Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385401.
  • 20
    Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In: TurkDC, MelzackR, editors. Handbook of pain assessment. New York: Guilford; 2001. p. 1534.
  • 21
    Dodd MJ, Miaskowski C, Lee KA. Occurrence of symptom clusters. J Natl Cancer Inst Monogr 2004; 32: 768.
  • 22
    Neuberger GB, Aaronson LS, Gajewski B, Embretson SE, Cagle PE, Loudon JK, et al. Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis. Arthritis Rheum 2007; 57: 94352.
  • 23
    Howards PP, Schisterman EF, Heagerty PJ. Potential confounding by exposure history and prior outcomes: an example from perinatal epidemiology. Epidemiology 2007; 18: 54451.
  • 24
    Danieli E, Airo P, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005; 24: 4854.
  • 25
    Rannou F, Poiraudeau S, Berezne A, Baubet T, Le-Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form health survey. Arthritis Rheum 2007; 57: 94102.
  • 26
    Johnson SR, Glaman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006; 33: 111722.
  • 27
    Georges C, Chassany O, Mouthon L, Tiev K, Marjanovic Z, Meyer O, et al. Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis. Rev Med Interne 2004; 25: 1621.
  • 28
    Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al, for the Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592600.
  • 29
    Hopman WM, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, Berger C, et al, and the Canadian Multicentre Osteoporosis Study Research Group. Canadian normative data for the SF-36 health survey. CMAJ 2000; 163: 26571.
  • 30
    Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, et al, and the National Comprehensive Cancer Network. NCCN Practice Guidelines for cancer-related fatigue. Oncology (Williston Park) 2000; 14: 15161.
  • 31
    Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. J Adv Nurs 2006; 56: 61735.
  • 32
    Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006; 24: 20738.
  • 33
    Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007; 22: 20706.
  • 34
    Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001; 161: 41120.
  • 35
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007; 46: 9991004.
  • 36
    Heiberg MS, Nordvag BY, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative effectiveness of tumor necrosis factor–blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005; 52: 250612.
  • 37
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594600.
  • 38
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793806.
  • 39
    Moreland LW, Genovese MC, Sato R, Singh A. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum 2006; 55: 28793.
  • 40
    Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998; 12: 36977.
  • 41
    Sadler IJ, Jacobsen PB, Booth-Jones M, Belanger H, Weitzner MA, Fields KK. Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manage 2002; 23: 40616.
  • 42
    Andrykowski MA, Schmidt JE, Salsman JM, Beacham AO, Jacobsen PB. Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvant therapy for breast cancer. J Clin Oncol 2005; 23: 661322.
  • 43
    Young KE, White CA. The prevalence and moderators of fatigue in people who have been successfully treated for cancer. J Psychosom Res 2006; 60: 2938.
  • 44
    Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005; 58: 17589.
  • 45
    Thombs BD, Hudson M, Taillefer SS, Baron M, and the Canadian Scleroderma Research Group. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthritis Rheum 2008; 59: 5049.
  • 46
    Thombs BD, Fuss S, Hudson M, Schieir O, Taillefer SS, Fogel J, et al. High rates of depressive symptoms among patients with systemic sclerosis are not explained by differential reporting of somatic symptoms. Arthritis Rheum 2008; 59: 4317.
  • 47
    Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007; 21: 15360.
  • 48
    Steen V. Targeted therapy for systemic sclerosis. Autoimmun Rev 2006; 5: 1224.